The presentation outlines the company's thesis focused on moving from AI adoption to delivering measurable economic outcomes through governed, autonomous decision-making. Key highlights from Q2FY27 performance include:
Financial Performance:
- Direct revenue grew 3.5% quarter-over-quarter (QoQ) and 11.3% year-over-year (YoY) in constant currency terms
- BFS Direct segment grew 4.5% QoQ and 15.0% YoY with a 3.8% compound quarterly growth rate over the past 8 quarters
- TMT Direct segment grew 10.9% QoQ and 14.5% YoY
- Insurance Direct grew 14.7% YoY
- Top 1-5 clients grew 15.1% YoY; Top 11-20 clients grew 22.7% YoY
Deal Wins and Pipeline:
- Quarterly Total Contract Value (TCV) wins: $466 million
- Trailing twelve-month (TTM) TCV: $1.8 billion
- 66% of TCV wins were AI-led deals
- Five large deals closed in Q2FY27
- 26% increase in <$20 million deal TCV on a TTM basis
- Pipeline at record levels with 23% growth YoY, with 71% of pipeline being AI-led
Segment Performance:
- Strong sequential growth in Americas and Rest of World (ROW) regions
- APPS and BPO growth driven by AI-led modernization deals and new deal wins
- Mphasis Tria-led process modernization deals emerging as a strong theme
Financial Metrics:
- Normalized cash generation for the quarter was $34 million after adjusting for $39.5 million of remittances initiated on September 30 and received in October
- Normalized Days Sales Outstanding (DSO) for the quarter was 105 days after the same adjustment
- Delivered stable margins within the stated range
Guidance for FY27:
- Revenue growth guidance: low double-digits despite uncertain macro environment
- Margin target: stable in the band of 14.75%–15.75%
- Target 80% conversion of Net income to Operating cash flow; normalized in FY28
Positioning and Strategy:
- The company is doubling down on AI with Mphasis Tria momentum continuing
- Focus on NeoZeta for AI-Driven Modernization and SDLC
- Emphasis on complex AI-led deals and NeoIP with sustained high TCV wins
- Foundry business unit partnership with AWS
The presentation also included standard forward-looking statements and risk factors typical for corporate disclosures.